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Abstract
Background: In the BACE trial, a 3-month (3m) intervention with azithromycin, initiated at the onset of an infectious
COPD exacerbation requiring hospitalization, decreased the rate of a first treatment failure (TF); the composite of
treatment intensification (TI), step-up in hospital care (SH) and mortality.
Objectives: (1) To investigate the intervention’s effect on recurrent events, and (2) to identify clinical subgroups most
likely to benefit, determined from the incidence rate of TF and hospital readmissions.
Methods: Enrolment criteria included the diagnosis of COPD, a smoking history of ≥10 pack-years and≥ 1 exacerbation
in the previous year. Rate ratio (RR) calculations, subgroup analyses and modelling of continuous variables using splines
were based on a Poisson regression model, adjusted for exposure time.
Results: Azithromycin significantly reduced TF by 24% within 3 m (RR = 0.76, 95%CI:0.59;0.97, p = 0.031) through a
50% reduction in SH (RR = 0.50, 95%CI:0.30;0.81, p = 0.006), which comprised of a 53% reduction in hospital
readmissions (RR = 0.47, 95%CI:0.27;0.80; p = 0.007). A significant interaction between the intervention, CRP and
blood eosinophil count at hospital admission was found, with azithromycin significantly reducing hospital
readmissions in patients with high CRP (> 50 mg/L, RR = 0.18, 95%CI:0.05;0.60, p = 0.005), or low blood eosinophil
count (<300cells/μL, RR = 0.33, 95%CI:0.17;0.64, p = 0.001). No differences were observed in treatment response by
age, FEV1, CRP or blood eosinophil count in continuous analyses.
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Conclusions: This post-hoc analysis of the BACE trial shows that azithromycin initiated at the onset of an infectious
COPD exacerbation requiring hospitalization reduces the incidence rate of TF within 3 m by preventing hospital
readmissions. In patients with high CRP or low blood eosinophil count at admission this treatment effect was more
pronounced, suggesting a potential role for these biomarkers in guiding azithromycin therapy.
Trial registration: ClinicalTrials.gov number. NCT02135354.
Keywords: Recurrent event, Readmission, Macrolide, CRP, Eosinophil count
Key questions
What is the key question?
A 3-month intervention with low-dose azithromycin, ini-
tiated at the onset of an infectious COPD exacerbation
requiring hospitalization, reduced treatment failure (a
novel composite primary endpoint) within 3 months of
hospital admission in the BACE trial. The intervention’s
effect on the individual exclusive subcomponents of
treatment failure and its effect in pre-specified clinical
subgroups are not known.
What is the bottom line?
This comprehensive recurrent-event post-hoc analysis
demonstrates that azithromycin significantly reduces the
rate of treatment failure within 3months of hospitalization
for an infectious COPD exacerbation by preventing subse-
quent hospital readmissions with 53%. This treatment
benefit is most pronounced in patients with either high
CRP (> 50mg/L) or low blood eosinophil count (< 300
cells/μL) at hospital admission.
Why read on?
Azithromycin may be a promising intervention to reduce
hospital readmissions in a COPD subgroup at high risk.
The present findings also suggest a potential role for
CRP and blood eosinophil count in guiding azithromycin
therapy.
Introduction
In the field of chronic obstructive pulmonary disease
(COPD), acute exacerbations (AECOPD) are considered
the most important determinants of a patient’s health
status [1–3]. They are characterized by an acute wors-
ening of respiratory symptoms that necessitate add-
itional therapy, based on which they are classified as
mild (treated with short-acting bronchodilators only),
moderate (requiring systemic corticosteroids and/or
antibiotics) or severe (requiring hospitalization) [4].
Hospital readmissions after an initial hospitalization for
an exacerbation (‘index event’) are associated with sig-
nificant morbidity, mortality and high resource
utilization [5], especially within the first 3 months after
hospital discharge [6].
We recently reported the results of the Belgian trial with
Azithromycin for acute COPD Exacerbations requiring
hospitalization (BACE, NCT02135354) [7]. The BACE
trial was an investigator-initiated randomized placebo-
controlled trial (RCT) comparing azithromycin (500mg
once a day for 3 days and subsequently administered for 3
months at 250mg every 2 days) with placebo on a novel
composite primary endpoint, treatment failure (TF).
Though formally negative on the primary endpoint (p =
0.0526), the applied time-to-first event analyses of its 3
subcomponents revealed that the reduction in TF rate
within 3months of hospital admission was mainly driven
by a significant decrease of treatment intensification with
systemic corticosteroids and/or antibiotics (TI), as well as
step-up in hospital care (SH) for respiratory reasons, while
no difference was observed for all-cause mortality. The
main analyses, however, limit our understanding to
‘whether’ and ‘when’ a first TF, or one of its subcompo-
nents, occurred [8].
In the present study, we aimed to investigate the inter-
vention’s effect on recurrent events, with a particular
focus on hospital readmissions. Based on a number of
pre-specified baseline patient characteristics, we add-
itionally aimed to identify clinical subgroups most likely
to benefit, determined from the incidence rate of TF and
hospital readmissions.
Methods
The study protocol [9] and primary findings [7] have
been published previously.
The BACE trial
The BACE trial was an investigator-initiated multicentre
randomized (1:1) double-blind placebo-controlled trial,
evaluating the effectiveness and safety of azithromycin,
initiated and uploaded (500 mg once a day for 3 days)
within 48-h of hospital admission for a severe infectious
AECOPD on top of a standardized acute treatment of
systemic corticosteroids and antibiotics (Additional file 1:
Table S1), and subsequently administered (250 mg every
2 days) for a prolonged period of 3 months (i.e., 90 days).
Patients were followed-up for 6 months thereafter. The
study consisted of 3 visits during hospitalization of the
index event: randomization (day 1), start of maintenance
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dose (day 4) and day of discharge (day X, at the investi-
gator’s discretion). After discharge, patients were
followed at the out-patient department at 1 month after
discharge (day X + 28), end of intervention (day 90) and
end of follow-up (day 270). Telephone calls were sched-
uled bimonthly (day 150 and day 210) between day 90
and day 270.
Patients were monitored for the primary endpoint, TF
within 3 months, at day 4, day X, day X + 28 and day 90.
TF was defined as the composite of (1) TI with systemic
corticosteroids and/or antibiotics for respiratory reasons,
(2) SH including transfer to the intensive care unit
(ICU) and hospital readmissions for respiratory reasons
or (3) all-cause mortality (Additional file 1: Table S2).
All patient characteristics were obtained at hospital ad-
mission (baseline), except for the spirometry values
which were obtained at day X.
The BACE trial was approved by the Commissie
Medische Ethiek UZ-KU Leuven (central ethics com-
mittee, ML10232). Written informed consent was ob-
tained from all participants.
Patients
The patient population had an established diagnosis of
COPD, a current or past smoking history of ≥10 pack-
years and ≥ 1 exacerbation treated with systemic cortico-
steroids and/or antibiotics in the previous year. The
main exclusion criteria were contraindications to azi-
thromycin, respiratory insufficiency requiring mec-
hanical or non-invasive ventilation at the time of
randomization, high-dose systemic corticosteroid use (>
4 mg methylprednisolone/day) for ≥2 months and the
use of macrolide antibiotics for ≥2 weeks preceding in-
clusion. A full list of exclusion criteria is provided in
Additional file 1: Table S3.
Statistical analyses
All post-hoc analyses were assessed in the intention-to-
treat population (n = 301), and were performed using R
v3.1.0 (R Core Team, Vienna, Austria) and SAS software
v9.4 (SAS Institute, Cary, NC, USA). Count data of TF
were analysed by deconstructing TF into exclusive hier-
archical subcomponents based on severity (for TF: mor-
tality > SH > TI; for SH: transfer to the ICU > hospital
readmission). TI was termed a moderate, and SH and
mortality a severe event. The incidence rates and rate ra-
tio’s (RR) were evaluated using a generalized linear
model for a Poisson distribution at day X, day 90, and
day 270, as well as the post discharge period between
day X and day 90, with treatment as factor and log-
transformed exposure time as offset. In order to obtain
the estimated incidence during 90 and 270 days, the esti-
mated daily rates were multiplied by 90 and 270, re-
spectively. For day X and the post discharge period, the
daily rates were multiplied by the median hospital (6
days) and post-hospital (83 days) time. The incidence
rates should be interpreted with caution as model as-
sumptions were not entirely met, particularly at day 270.
To assess whether the intervention’s effect on the total
number of TFs and hospital readmissions within 3
months varied according to 9 pre-specified baseline pa-
tient characteristics, Poisson regression models were
used with log-transformed time in the study as offset
and treatment, subgroup and their interaction as factors
in the model. In these subgroup analyses, TF was de-
fined the composite of the individual subcomponents
and hospital readmission included readmissions result-
ing in ICU transfer or mortality. For CRP and blood
eosinophil count at admission, the analysis was addition-
ally stratified for treatment with systemic corticosteroids
prior to hospital admission to control for potential con-
founding [10].
Further analyses were performed for 4 subgroups
based on continuous variables (age, CRP, FEV1 and
blood eosinophil count), in which the continuous vari-
able was included in the model as a restricted cubic
spline to allow for any type of association with the
outcome.
All tests were two-sided and assessed at a significance
level of 5%. Due to exploratory nature of the analyses,
no adjustments were made to the significance level to
account for multiple testing.
Results
Patients
The present recurrent-event analyses included the
intention-to-treat population reported in the primary
time-to-first event analyses [7]. The key baseline charac-
teristics of the 301 patients, randomized to azithromycin
(n = 147) or placebo (n = 154), are summarized in
Table 1. The extended version is available in the Add-
itional file 1: Table S4. There were no statistically signifi-
cant group differences.
Recurrent events
Within 3 months of randomization, a total of 248 TFs
occurred: 106 in the azithromycin versus 142 in the pla-
cebo group (Table 2), resulting in a significant reduction
of 24% (RR = 0.76, 95%CI 0.59;0.98, p = 0.031) (Fig. 1a).
When decomposing TF in its exclusive hierarchical sub-
components, there was a nominal decrease in all-cause
mortality (RR = 0.61, 95%CI 0.13;2.48, p = 0.498), a sta-
tistically significant reduction of 50% in SH in favour of
azithromycin over placebo (RR = 0.50, 95%CI 0.30;0.81,
p = 0.006) (Fig. 1b) and no difference in TI (RR = 0.90;
95%CI 0.67;1.22, p = 0.508). All benefits were lost 6
months after treatment withdrawal, however, SH
remained considerably reduced (RR = 0.75, 95% CI 0.56;
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1.00, p = 0.053). 47 TFs (19%) occurred during the
hospitalization period of the index AECOPD and were
mainly moderate events: 18 in the azithromycin versus
24 in the placebo group (RR = 0.83, 95%CI 0.44;1.52, p =
0.544) (Fig. 1b). 201 TFs (81%) occurred during the
post-discharge period while on study medication (3-
month maximum) and consisted of 64% moderate (n =
128; 62 in the azithromycin versus 66 in the placebo
Table 1 Baseline characteristics
Azithromycin
(N = 147)
Placebo
(N = 154)
Demographics
Age – years 66 ± 9 67 ± 10
Female sex – no. (%) 66 (45) 66 (43)
BMI – kg/m2 24.5 ± 5.9 25.1 ± 6.5
Comorbidity
Charlson comorbidity index 4 [3–5] 4 [3–5]
Lung disease
mMRC dyspnea score 4 [2–4] 4 [2–4]
Pre-bronchodilator FEV1 – L 0.90 [0.69–1.23] 0.95 [0.71–1.36]
Pre-bronchodilator FEV1 – % pred. 36.0 [26.3–53.8] 38.5 [29.0–52.0]
Pre-bronchodilator FEV1/FVC – % 40.3 [33.6–48.0] 45.0 [37.0–52.8]
GOLD stage – no. (%)a
A 0 (0) 1 (1)
B 26 (18) 30 (20)
C 1 (1) 2 (1)
D 120 (82) 121 (79)
Current smoker – no. (%) 63 (43) 65 (42)
Smoking history – pack-years 44 [37–50] 43 [35–50]
Inhaled therapy for COPD – no. (%)
LABA 136 (93) 145 (94)
LAMA 118 (80) 123 (80)
Inhaled corticosteroids 118 (80) 123 (80)
SABA 108 (73) 109 (71)
Admission presentation
GP intervention prior to admission – no. (%)
Systemic corticosteroids 48 (33) 37 (24)
Antibiotics 50 (34) 54 (35)
Laboratory
C-reactive protein (mg/L) 14.2 [3.5–61.4] 21.6 [4.5–59.6]
Leucocytes (× 109/L) 10.95 [9.00–13.89] 9.90 [8.20–13.70]
Neutrophils (×109/L) 8.20 [6.00–11.20] 7.70 [5.60–11.20]
Eosinophils (× 109/L) 0.06 [0.00–0.20] 0.07 [0.00–0.20]
Standardized acute treatment
Received – no. (%) 134 (91) 141 (92)
Received antibiotic – no. (%) 145 (99) 152 (99)
Pathogen susceptible to antibiotic b − no. (%) 136 (94) 144 (95)
Data are presented as either no. (%), mean ± SD or median [Q1-Q3 interquartile range]
Abbreviations: COPD Chronic obstructive pulmonary disease, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity, GOLD Global initiative for chronic
Obstructive Lung Disease, guideline 2017, GP General practitioner, LABA Long-acting beta-agonist, LAMA Long-acting muscarinic antagonist, mMRC Modified
Medical Research Council questionnaire, SABA Short-acting beta-agonist
aGOLD stages are not taking the current hospital admission into consideration. bSusceptibility was determined based on the need for antibiotic upgrade prior to
discharge. Change or narrowing of the initial antibiotic based on proven bacterial cultures was considered good clinical practice
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group; RR = 0.95 (95%CI 0.67;1.34), p = 0.757) and 36%
severe events (n = 73; 25 in the azithromycin versus 48 in
the placebo group; RR = 0.52 (95%CI 0.32;0.84), p = 0.009).
When assessing the subcomponents of SH within 3
months (Fig. 1c), a non-significant 32% reduction in trans-
fer to the ICU (RR = 0.68, 95% CI 0.17;2.37, p = 0.546) was
observed, as well as a significant 53% reduction in hospital
readmissions (RR = 0.47, 95%CI 0.27;0.80; p = 0.007) after
hospital discharge of the index AECOPD.
Clinical subgroups
Subgroups based on 9 baseline covariates were assessed
for the incidence rate of TF and hospital readmissions
within 3months. While no statistically significant inter-
actions were observed between the intervention and any
of the subgroups for the incidence rate of TF (Table 3),
a significant interaction effect was observed between the
intervention and baseline CRP levels (pinteraction =
0.0349) for hospital readmissions. Patients with high
baseline CRP (> 50mg/L) treated with azithromycin had
significantly fewer hospital readmissions within 3
months, as compared to placebo (RR = 0.18, 95%CI 0.05;
0.60, p = 0.0053) (Table 4). Furthermore, a significant
interaction effect was observed between the intervention
and blood eosinophil count at hospital admission (pinter-
action = 0.0172). Patients with a baseline eosinophil count
< 300 cells/μL treated with azithromycin had signifi-
cantly fewer hospital readmissions within 3 months, as
compared to placebo (RR = 0.33, 95%CI 0.17;0.64, p =
0.0012) (Table 4). In contrast, patients with a baseline
eosinophil count > 300 cells/μL did not show a signifi-
cant effect on hospital readmission rate when treated
with azithromycin. Prior to hospital admission, 28%
(n = 85) of the randomized patients had received treat-
ment with systemic corticosteroids from their general
practitioner. In the non-pretreated patients, the observed
interaction between the intervention and both high CRP
and low blood eosinophil count for the incidence rate of
hospital readmissions remained statistically significant,
whereas in the pretreated patients no significant inter-
action was observed (Table 5).
From spline modelling, neither age, FEV1 (Additional
file 1: Figure S1), CRP nor blood eosinophil count (Fig. 2)
were significantly associated with the incidence rate of
TF or hospital readmissions. Notably, a p-value of 0.094
was observed for the interaction between blood eosino-
phil count at hospital admission and the incidence rate
of hospital readmissions within 3 months.
Discussion
The BACE trial was an investigator-initiated, random-
ized, double-blind, placebo-controlled trial evaluating a
3-month intervention with low-dose azithromycin, initi-
ated at the onset of a severe infectious AECOPD requir-
ing hospitalization. Although formally negative on the
composite primary endpoint (TF rate within 3months,
p = 0.0526), secondary time-to-first event analyses dem-
onstrated a significant 21 and 52% reduction in the rate
of TI and SH for respiratory reasons, respectively [7].
The present post-hoc analyses were performed to further
elucidate the intervention’s effect on recurrent events, in
particular hospital readmissions, and demonstrate that
azithromycin reduces the TF rate within 3 months of a
severe AECOPD by preventing subsequent hospital
readmissions with more than 50%.
COPD is a chronic disease, typically characterized by
recurrent exacerbations as the patient’s condition pro-
gressively deteriorates [11]. Severe exacerbations requir-
ing hospitalization are the number one contributor to
the overall burden and cost of the disease [5], warranting
targeted interventions to reduce these readmissions. In
the BACE trial, first events accounted for only 63% of
Table 2 Count data
Azithromycin
(n = 147)
Placebo
(n = 154)
a) Number of first events Day 90 Day 270 Day 90 Day 270
Treatment failure 69 112 86 119
b) Number of recurrent events Day X Day 90 Day 270 Day X Day 90 Day 270
Treatment failure 19 106 306 28 142 322
Treatment intensification 18 80 217 24 90 206
Step-up in hospital care 0 23 82 2 47 107
Transfer to the ICU 0 4 13 2 6 15
Hospital readmission – 19 69 – 41 92
Mortality 1 3 7 2 5 9
Number of (a) first and (b) recurrent events of the primary composite endpoint, treatment failure, and its 3 exclusive subcomponents: treatment intensification,
step-up in hospital care (comprised of transfer to the ICU and hospital readmissions) and mortality prior to hospital discharge (day X, median: 6 [Q1-Q3
interquartile range: 4–8] days), within 90 and 270 days
day x, day of discharge, at the investigator’s discretion; day 90, end of intervention; day 270, end of follow-up
Abbreviations: ICU Intensive care unit
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the total number of TFs within 3 months. Though con-
ventionally applied, restricting the efficacy analyses to
first events would therefore incompletely represent the
intervention’s effect on the patient’s overall burden of
disease. Moreover, as time-to- first TF was defined as a
composite endpoint, with no hierarchy among the
Fig. 1 Incidence rate and rate ratio calculations prior to hospital discharge (day X, median: 6 [Q1-Q3 interquartile range: 4–8] days), within 90 and
270 days of a the primary composite endpoint, treatment failure, b its 3 exclusive subcomponents: treatment intensification, step-up in hospital
care and mortality, and c step-up in hospital care’s 2 exclusive subcomponents: transfer to the ICU and hospital readmissions. Abbreviations: ICU,
intensive care unit. Note: day x, day of discharge, at the investigator’s discretion; day 90, end of intervention; day 270, end of follow-up; *,
indicates significant difference
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different subcomponents, 98% of TFs were first captured
by TI even though they were subsequently accompanied
by SH or mortality. To provide insight into the true
components of TF, the present analyses focus on the ex-
clusive hierarchical subcomponents ranked by severity
(mortality > transfer to ICU > hospital readmission > TI
with systemic corticosteroids and/or antibiotics). In
doing so, we demonstrated that azithromycin reduces
the incidence rate of TF at 3 months mainly by reducing
subsequent hospital readmissions with 53%, while a clin-
ically relevant though statistically not significant 32% re-
duction in the transfers to the ICU was also observed.
Conversely, we found that azithromycin did not affect
the overall incidence rate of moderate events (i.e., treat-
ment intensification not resulting in hospital admission,
transfer to ICU or mortality), which – in part – could
account for the lack of statistically significant differences
in quality of life and symptom assessment scores ob-
served in the BACE trial [7]. When compiled, the BACE
trial results substantiate previous findings suggesting azi-
thromycin may be most effective in preventing severe
AECOPD requiring hospitalization [12–14]. Azithromy-
cin appears to modify the severity of new exacerbations,
so that this high risk subgroup may be less likely to
require hospitalization when they do experience new ex-
acerbations. The BACE trial is the first macrolide study
in COPD to identify this affordable therapeutic option as
a much desired intervention to safely reduce hospital
readmissions. Potential adverse effects related to the
intervention were discussed previously [7]. No group dif-
ferences were observed in the number of SH, its exclu-
sive subcomponents (transfer to the ICU and hospital
readmissions) or mortality between treatment with-
drawal (day 90) and 6months of follow-up (day 270),
supporting earlier time-to-first event analysis findings
that prolongation of intake is needed to maintain azi-
thromycin’s clinical benefits. Notably, an increased num-
ber of TI in the azithromycin group compared to the
Table 3 Subgroup analyses of the incidence rate of treatment failure within 90 days, in the intention-to-treat population
low CRP: ≤50mg/L; high CRP: > 50 mg/L
Abbreviations: CRP C-reactive protein, GOLD Global initiative for chronic Obstructive Lung Disease, guideline 2017, ICS Inhaled corticosteroid
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placebo group underlies an increase in the number of
TF when withdrawing azithromycin.
In the BACE trial, azithromycin was uploaded within
48 h post emergency admission, as potential benefits
during the index event were hypothesized to contribute
to the overall effect on the primary endpoint. Prior to
hospital discharge, azithromycin tended to reduce the
incidence rate of TF within 6 days compared to placebo
(25% reduction, with a 17 and 45% reduction in TI and
all-cause mortality, respectively). These observations
were not statistically significant as the study remained
largely underpowered for any conclusions on potential
benefits during the index event. Several studies, however,
have demonstrated that bacterial eradication in the acute
phase may result in better long-term outcomes, includ-
ing readmission rates [15–17]. Future prospective ran-
domized placebo-controlled trials with azithromycin are
therefore highly encouraged to evaluate the added value
of azithromycin in the acute setting of a severe
AECOPD, in addition to a limited prolonged administra-
tion to prevent relapse. At this stage, it is up to the clin-
ician to decide when prolonged therapy with macrolides
is indicated. Based on the BACE trial findings, patients
with COPD suffering from severe infectious exacerba-
tions are at least a target subgroup that needs proper
consideration.
The treatment effect of azithromycin appeared to
differ according to baseline CRP levels at hospital ad-
mission for the index event. Serum CRP has been
identified as a relatively sensitive and specific bio-
marker to distinguish patients who require antibiotics
[18, 19], with previous studies showing that a cut-off
value of 50 mg/L for high CRP is most optimal to de-
termine antibiotic needs [20–22]. We observed a large
and statistically significant effect of azithromycin on
hospital readmissions within 3 months in patients with
high CRP at baseline (31% of the studied population).
This may suggest that the antibacterial effect of
Table 4 Subgroup analyses of the incidence rate of hospital readmissions within 90 days, in the intention-to-treat population
low CRP: ≤50mg/L; high CRP: > 50 mg/L
Abbreviations: CRP C-reactive protein, GOLD Global initiative for chronic Obstructive Lung Disease, guideline 2017, ICS Inhaled corticosteroid
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azithromycin is the dominant mechanism, although
one may argue that all patients were already treated
with an effective antibiotic as part of the standardized
treatment during the index event. These findings
complement the observed 23% significant reduction in
the total days of antibiotic use within 3 months in the
azithromycin group when compared to placebo (a
pre-specified secondary endpoint of the main analysis,
p < 0.0001) [7]. Similarly, however, azithromycin was
found to be more effective in patients with absence of
blood eosinophilia at baseline, which corroborates
previous findings that high eosinophilia is a good
marker for the need of systemic corticosteroids [23].
This observation is biologically plausible, since macro-
lides have been shown to be effective in neutrophilic
chronic airway diseases and might be due to anti-
inflammatory and immunomodulatory effects in
addition to azithromycin’s antibiotic properties. Al-
though it is tempting to speculate that in AECOPD
with high blood eosinophilia azithromycin has no
added value, such biomarker guided treatment is
needing prospective studies before broad implementa-
tion can be recommended. It is currently unknown to
what degree azithromycin’s antimicrobial and anti-
inflammatory properties contribute to the compiled
BACE trial findings. As long as we have no macro-
lides available that are completely stripped of their
antibiotic properties, any further understanding of the
mechanism leading to its clinical benefits will be
influenced by this dual mode of action.
Through continuous spline modelling, neither age,
FEV1, CRP nor blood eosinophil count could be identified
as possible predictors of azithromycin response, deter-
mined from the incidence rate of TF and hospital read-
missions within 3months. However, we did observe a
trend for a negative association between blood eosinophil
count at hospital admission for a severe AECOPD and the
incidence rate of hospital readmissions within 3months in
patients treated with azithromycin.
The findings of the present study must be inter-
preted in the context of several potential limitations.
Most importantly, this is a post-hoc analysis of a trial
which was underpowered for the assessment of the
primary endpoint (p = 0.0526) due to early termin-
ation for slow recruitment. Not observing significant
interactions between any of the examined baseline
variables and the treatment effect of azithromycin
may therefore have been the result of type II errors.
Likewise, significant associations obtained from the
subgroup analyses may have resulted from an inflated
Table 5 Subgroup analyses of the incidence rate of (a) treatment failure (upper panels) and (b) hospital readmissions (lower panels)
within 90 days, in the intention-to-treat population, stratified for treatment with systemic corticosteroids prior to hospital admission
low CRP: ≤50mg/L; high CRP: > 50 mg/L, pretreated patients (panels left), non-pretreated patients (panels right)
Abbreviations: CRP C-reactive protein
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type I error rate, as multiple analyses were performed
simultaneously. Furthermore, a cautious interpretation
of the findings at day 270 is warranted as not all
model assumptions could be met. Prospective and ad-
equately powered clinical trials are therefore needed
to verify our hypothesis-generating findings. Second,
while TF (as well as each of its subcomponents) al-
lows for a continuous risk exposure during the
hospitalization period of the index exacerbation and
the post discharge period, a possible difference in ex-
posed risk was not accounted for when calculating
the incidence rates. Finally, although studies in COPD
have examined thresholds for blood eosinophil counts
and CRP levels, it has not yet been defined which
measurement – on a continuous rather than a dichot-
omous scale – is most appropriate to predict treat-
ment response as a biomarker.
Conclusion
In conclusion, a 3-month intervention with low-dose
azithromycin for severe infectious AECOPD requiring
hospitalization appears to reduce the rate of treatment
failure within 3months mainly by preventing subsequent
hospital readmissions. This complements the BACE tri-
al’s main finding that azithromycin may be a promising
and cost-saving therapy for a subgroup of patients with
the highest unmet needs. Although rigorous prospective
studies are required, the present findings also suggest a
potential role for CRP and blood eosinophil count at ad-
mission in guiding azithromycin therapy in patients with
a severe AECOPD.
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